Can a Spot Urine Replace or Improve 24 Hour Urine Collections in Kidney Stone Patients
Launched by UNIVERSITY OF BRITISH COLUMBIA · Aug 17, 2011
Trial Information
Current as of July 05, 2025
Terminated
Keywords
ClinConnect Summary
BACKGROUND Urinary stone disease is a common problem, causing significant morbidity and sometimes mortality. Stone disease affects 5-10% of the population during their lifetime and of these patients between 30-50% will have at least one recurrent episode.
Urinary stones arise due to crystallization and aggregation of supersaturated ion complexes in the urine. Depending on the concentration of various urinary constituents and the physicochemical characteristics of a given individual's urine (such as pH, volume, calcium citrate concentration etc.), different crystals may precipitate. Therefo...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients who have been diagnosed as having calcium based urinary stones
- • at least 19 years of age
- • do not have any additional serious disease
- Exclusion Criteria:
- • Patients who do not have calcium based urinary stones (such as: uric acid, cystine, struvite)
- • less than 19 years of age
- • have a serious alternate disease
- • Pregnancy
- • Positive Urine Culture
- • Active cancer
- • Recurrent urinary infections
- • Gross hematuria
- • Receiving treatment with thiazides (or alternatively can be enrolled if the patient is willing to stop treatment for 2 weeks prior to study)
- • Inability to provide informed consent
- • Investigator's refusal to include
About University Of British Columbia
The University of British Columbia (UBC) is a leading research institution located in Vancouver, Canada, renowned for its commitment to advancing health sciences through innovative research and education. As a prominent clinical trial sponsor, UBC leverages its interdisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies aimed at improving patient outcomes across various medical fields. The university fosters collaborations with healthcare professionals, industry partners, and community stakeholders to translate research findings into practical applications, thereby contributing to the global advancement of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vancouver, British Columbia, Canada
Patients applied
Trial Officials
Ryan Paterson
Study Director
University of British Columbia
Roger Sutton
Study Director
University of British Columbia
Morris Pudek
Study Director
University of British Columbia
Dirk Lange
Study Director
University of British Columbia
Meredith Cushing
Study Director
Vancouver General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials